Company profile PGEN

Precigen Inc
precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies.... in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua Show More
Quarter analysis & expected interest

There is not enough data for Precigen gene therapy to provide analysis

Correlation between past revenue and Precigen gene therapy search interest

There is not enough data for Precigen gene therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen gene therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen gene and cellular therapies to provide analysis

Correlation between past revenue and Precigen gene and cellular therapies search interest

There is not enough data for Precigen gene and cellular therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen gene and cellular therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen biotechnology to provide analysis

Correlation between past revenue and Precigen biotechnology search interest

There is not enough data for Precigen biotechnology to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen biotechnology to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen UltraVector platform to provide analysis

Correlation between past revenue and Precigen UltraVector platform search interest

There is not enough data for Precigen UltraVector platform to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen UltraVector platform to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen mbIL15 gene to provide analysis

Correlation between past revenue and Precigen mbIL15 gene search interest

There is not enough data for Precigen mbIL15 gene to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen mbIL15 gene to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen rheoswitch therapeutic system to provide analysis

Correlation between past revenue and Precigen rheoswitch therapeutic system search interest

There is not enough data for Precigen rheoswitch therapeutic system to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen rheoswitch therapeutic system to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen kill switches to provide analysis

Correlation between past revenue and Precigen kill switches search interest

There is not enough data for Precigen kill switches to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen kill switches to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen ActoBiotics platform to provide analysis

Correlation between past revenue and Precigen ActoBiotics platform search interest

There is not enough data for Precigen ActoBiotics platform to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen ActoBiotics platform to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen corporate governance to provide analysis

Correlation between past revenue and Precigen corporate governance search interest

There is not enough data for Precigen corporate governance to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen corporate governance to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Precigen ISS governance qualityscore to provide analysis

Correlation between past revenue and Precigen ISS governance qualityscore search interest

There is not enough data for Precigen ISS governance qualityscore to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Precigen ISS governance qualityscore to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for PGEN
Earnings date: 2024-02-29 After close
Company name: Precigen Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-09-25T09:20:39.497595353Z

Analyst Upgrades
B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12

2026-09-21T07:00:00-04:00

PR Newswire
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

2026-08-25T07:00:00-04:00

AccessWire
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers

2026-08-05T10:43:59.885174263Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $18

2026-08-04T16:01:00-04:00

PR Newswire
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

2026-08-03T11:36:37.417208082Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $14 Price Target

2026-07-21T08:00:00-04:00

PR Newswire
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

2026-06-15T10:40:00Z

AccessWire
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

2026-06-11T08:00:00-04:00

PR Newswire
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

2026-05-30T14:30:00-04:00

PR Newswire
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

2026-05-28T10:52:16Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $14

2026-05-27T07:00:00-04:00

PR Newswire
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

2026-05-26T08:05:00-04:00

PR Newswire
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-14T14:15:42Z

Analyst Upgrades
Citizens Maintains Market Outperform on Precigen, Raises Price Target to $11

2026-05-14T10:38:11Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $11